Aquestive Therapeutics, Inc.

NASDAQ:AQST

Drug Manufacturers - Specialty & Generic

Healthcare
$3.78 +5.08%

+$0.23 today

Market cap
$475.10M
Beta
1.45
P/E (TTM)
-8.3
EPS (TTM)
-$0.56
52W Low $2.93High $7.55

Volume 1.80M

Average 1.51M

AQST Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Aquestive Therapeutics, Inc.NASDAQ: AQST

Net Debt · Q1 FY2026 · quarter ended Mar 2026

Net debt turns positive

Q1 FY2026 net debt was $22.84M, compared with -$29.52M a year earlier. Over 3 fiscal years it compounded at -30.2% a year.

Context

  • Net debt amounted to 16.2% of total assets at the end of Q1 FY2026, down 12.7 pp from a year earlier.
  • Net debt increased in 1 of the last 3 fiscal years.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +177.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$22.84M+122.3% QoQ
Last fiscal yearDec 2025
$10.28M+130.6% YoY
Year agoMar 2025
-$29.52M+177.4% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+177.4%——
1 year+130.6%——
3-year CAGR-30.2%——
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
10.28M USD
Year-over-year change
+130.6%
4-year CAGR
-22.4%

Net Debt vs competitors

How AQST compares with its peers on the latest reported figures

  • AQST's Mar 2026 net debt of $22.84M is the 4th highest of the 10 companies compared; the peer median is -$1.75M.
  • Its year-over-year change of +177.4% is the 2nd highest of 10, against a peer median of -23.8%.
  • Net debt amounts to 16.2% of total assets for AQST, versus a peer median of 19.0%.
AQST Competitors Peer median
Net Debt for AQST and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALKSAlkermes plcSep 2026$939.77M +272.5%—21.2%
COLLCollegium Pharmaceutical, Inc.Mar 2026$539.41M -27.9%+8.8%32.7%
AMPHAmphastar Pharmaceuticals, Inc.Mar 2026$515.2M +9.7%—31.3%
AQSTAquestive Therapeutics, Inc.Mar 2026$22.84M +177.4%-30.2%16.2%
CPIXCumberland Pharmaceuticals Inc.Mar 2026-$937.46K +79.9%—1.3%
DERMJourney Medical CorporationMar 2026-$1.75M -142.8%—1.9%
VNDAVanda Pharmaceuticals Inc.Mar 2026-$40.96M +59.1%—9.4%
XERSXeris Biopharma Holdings, Inc.Mar 2026-$74.42M -135.4%—19.0%
ZVRAZevra Therapeutics, Inc.Mar 2026-$94.45M -485.5%—33.9%
SUPNSupernus Pharmaceuticals, Inc.Jun 2026-$139.78M -23.8%—9.8%
Peer median (excluding AQST) -$1.75M-23.8%+8.8%19.0%

Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents28.02M27.27M23.87M71.55M121.17M
Short-term Investments00000
Net Receivables12.12M4.7M8.47M7.34M17.76M
Inventory4.04M5.78M6.77M6.04M6.17M
Other Current Assets02.13M1.85M3.29M4.17M
Total Current Assets47.26M39.89M40.97M88.22M149.27M
Property, Plant & Equipment (Net)7.78M9.3M9.74M8.98M8.51M
Goodwill00000
Intangible Assets51K1.44M1.28M00
Long-term Investments6M04M3M2M
Tax Assets(6M)0000
Other Non-current Assets6.9M6.45M1.44M1.22M642K
Total Non-current Assets14.73M17.18M16.45M13.2M11.16M
Total Assets61.99M57.07M57.42M101.42M160.43M
Account Payables8.31M9.95M8.93M10.29M29.86M
Short-term Debt2.03M18.7M22K26K11.63M
Tax Payables349K322K337K365K0
Deferred Revenue765K1.51M1.55M1.05M1.09M
Other Current Liabilities7.19M7.54M5.12M1M1.32M
Total Current Liabilities21.96M39.53M18.31M18.87M47.61M
Long-term Debt51.55M33.45M27.51M32.5M115.48M
Deferred Tax Liabilities59.06M0000
Deferred Revenue (Non-current)7.12M31.42M32.35M20.01M19.39M
Other Non-current Liabilities2.49M66.15M80.35M85.24M7.27M
Total Non-current Liabilities122.16M136.1M145.6M142.72M146.48M
Total Liabilities144.13M175.62M163.91M161.58M194.09M
Common Stock41K55K69K91K122K
Retained Earnings(256.8M)(311.21M)(319.08M)(363.21M)(447M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity(82.13M)(118.55M)(106.49M)(60.16M)(33.66M)
Total Debt56.42M57.49M33.32M38M131.45M
Net Debt28.4M30.22M9.45M(33.54M)10.28M

Aquestive Therapeutics, Inc.

NASDAQ:AQST

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.